Secukinumab: a review in ankylosing spondylitis
HA Blair - Drugs, 2019 - Springer
Secukinumab (Cosentyx®), a first-in-class fully human monoclonal antibody against
interleukin-17A, is approved in several countries, including the USA and those of the EU, for …
interleukin-17A, is approved in several countries, including the USA and those of the EU, for …
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial …
Background Recent developments improved outcomes in patients with autoimmune
diseases. Biologics were approved as first-line treatment in selected naïve patients with …
diseases. Biologics were approved as first-line treatment in selected naïve patients with …